China: Youth Drug Use Drops 41.6%, 16 New Substances Banned

China’s National Narcotics Control Office (NNCO) announced on Wednesday that newly identified drug users under the age of 35 dropped by 41.6% year-on-year in 2025, while simultaneously adding 16 new substances to the national controlled substances list in a dual-pronged effort to combat drug abuse. The announcements, made at a press conference in Beijing, highlight both the progress of China’s youth-focused prevention campaigns and the escalating challenge of regulating emerging synthetic drugs.

Context: A Two-Pronged Strategy

The NNCO’s latest data, reported by The Paper, reveals that 197,000 anti-drug education campaigns were organized nationwide in 2025, directly reaching 450 million people. These efforts were coordinated across seven central government agencies, including the Central Cyberspace Affairs Office and the Ministry of Education, with a particular focus on minors and school-aged youth. A “Five Ones” special education program was implemented for students returning to school in the autumn, and a National Youth Anti-Drug Knowledge Competition was held to reinforce prevention messaging.

Wei Xiaojun, Executive Deputy Director of the NNCO and Director of the Narcotics Control Bureau at the Ministry of Public Security, stated at the press conference that the campaigns have “significantly improved young people’s awareness of drug abuse prevention.”

Broader Enforcement Trends

The decline in youth drug use is part of a broader downward trend in drug-related enforcement. According to the 2025 China Drug Situation Report, published by China Daily, authorities investigated and processed 134,000 drug users in 2025 — a 30.3% decline year-on-year. Police solved 27,000 drug-related criminal cases (down 27.6%) and arrested 41,000 suspects (down 33%).

However, the amount of drugs seized rose sharply — 33.5 tons, an increase of 25.4% — suggesting that while overall drug activity may be declining, enforcement efforts are intercepting larger quantities. As of the end of 2025, 4.403 million people had remained abstinent for three or more years without relapse, up 2.7% year-on-year.

New Controlled Substances

In a separate but related development, the NNCO announced the addition of 16 new substances to the “Catalogue of Non-Medicinal Narcotic Drugs and Psychotropic Substances,” as reported by Xinhua News. The newly listed substances include difluoroethylmidazole (二氟乙咪酯) and tiletamine (替来他明), with the latter carrying an exemption for veterinary preparations already approved for sale in China. The new regulations take effect on July 1, 2026.

With this addition, China now controls 412 individual non-medicinal narcotic drugs and psychotropic substances, plus three whole categories: fentanyl-type, synthetic cannabinoid-type, and nitazene-type substances. The classification of entire chemical categories represents a preemptive regulatory approach — banning whole classes of chemically related substances rather than listing them individually — a strategy China adopted for fentanyl-type substances in 2019 and synthetic cannabinoids in 2021.

The Emerging Challenge of Unlisted Substances

Despite the encouraging decline in youth drug use, the 2025 data reveals a rapidly evolving synthetic drug landscape that poses new challenges. According to the China Daily report, seizures of nitrous oxide — commonly known as “laughing gas” — surged 84% year-on-year to 1.265 million liters. Even more striking, seizures of other unlisted addictive substances, including alkyl nitrites (“Rush”) and tiletamine, reached 9.3 tons — a 17.6-fold increase compared to the previous year.

This surge highlights a critical vulnerability in China’s drug control framework: as soon as one substance is banned, chemists can modify molecular structures to create legal alternatives that evade existing regulations. The result is a “cat-and-mouse” dynamic between regulators and producers, with the data suggesting the problem is accelerating rather than diminishing.

Analysis and Implications

The 41.6% decline in newly identified youth drug users represents a significant achievement for China’s prevention-focused strategy. The multi-department coordination, mass education campaigns, and school-based programs appear to be having measurable impact on youth drug experimentation. However, the figure represents newly identified users rather than total prevalence, and some of the decline could reflect a shift toward unlisted substances that may not be captured in traditional statistics.

China’s approach stands in contrast to more harm-reduction-oriented policies in some Western countries. The emphasis on strict prohibition, mass education, and rehabilitation reflects China’s broader governance model, where centralized coordination across multiple government agencies enables large-scale public health campaigns.

What to Watch For

The new controlled substances list takes effect on July 1, 2026, and authorities will be watching closely to see whether the ban on difluoroethylmidazole and the other 15 substances drives users toward yet-unknown alternatives. The 17.6-fold surge in unlisted substance seizures suggests that China’s regulatory net, while expanding, may need to evolve faster to keep pace with chemically innovative drug producers. The effectiveness of whole-category bans — already applied to fentanyls, synthetic cannabinoids, and nitazenes — will be a key indicator of whether this preemptive strategy can outpace the emerging drug landscape.